藍帆醫療(002382.SZ):暫不向下修正“藍帆轉債”的轉股價
格隆匯3月8日丨藍帆醫療(002382.SZ)公佈,截至2023年3月8日,公司股票已出現連續三十個交易日中至少有十五個交易日的收盤價低於當期轉股價格85%的情形,已觸發“藍帆轉債”轉股價格向下修正條件。
經公司第五屆董事會第三十次會議審議通過,公司董事會決定本次不向下修正“藍帆轉債”轉股價格,且自本次董事會審議通過之日起的六個月內(2023年3月8日至2023年9月7日),如再次觸發“藍帆轉債”轉股價格向下修正條件,亦不提出向下修正方案。自2023年9月8日之後,若再次觸發“藍帆轉債”轉股價格的向下修正條件,屆時公司董事會將再次召開會議決定是否行使“藍帆轉債”轉股價格的向下修正權利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.